世界中医药2017，Vol.12Issue(8)：1936-1940,5.DOI:10.3969/j.issn.1673-7202.2017.08.053
小儿肠胃康颗粒治疗小儿腹泻疗效及安全性的Meta分析
Efficacy and Safety of Xiaoerchangweikangkeli on Children with Diarrhea:A Meta-Analysis
摘要
Abstract
Objective:To evaluate the efficacy and safety of Xiaoer Changweikang Keli in the treatment of diarrhea in children using a meta-analytic method.Methods:We searched PubMed,Embase,The Cochrane Library (Issue 6,2015),CBM,CNKI,VIP and WanFang Databases from their inception to June,2015,to collect randomized controlled trials (RCTs) or quasi-RCTs of Xiaoerchan gweikangkeli for diarrhea in children.Two researchers independently screened literature according to the pre-specified inclusion and exclusion criteria,extracted data and evaluated the risk of bias of included studies.RevMan 5.3 software was used for all analysis.Results:A total of 13 studies including 1395 patients were included.The results of meta-analysis showed that,compared with control group,combined medication of the Xiaoerchangweikangkeli had significant improvement in overall efficacy rate 4.20 times (RR =4.20,95％ CI 2.93 to 6.03,P ＜ 0.05).Subgroup analysis according to type of diarrhea,compared with the control group,the Xiaoerchangweikangkeli had significant improvetment in efficacy for autumn diarrhea 4.30 times (RR =4.30,95％ CI 2.24 to 8.27,P ＜ 0.05) and lienteric diarrhea 3.92 times (RR =3.92,95％ CI 2.51 to 6.11,P ＜ 0.05).Conclusion:Current evidence showed that compared with independent use of other drugs,combined medication of Xiaoerchangweikangkeli could improve the overall efficacy rate for diarrhea in children,especially for autumn diarrhea and lienteric diarrhea.However,due to limited quality and sample size of included studies,more high quality studies with large sample size are necessary to verify the results.关键词
小儿肠胃康颗粒/小儿腹泻/随机对照试验/Meta分析Key words
Xiaoerchangweikangkeli/Diarrhea in children/Randomized controlled trial/Meta-analysis分类
医药卫生引用本文复制引用
马融,付竹,曾宪涛,翁鸿..小儿肠胃康颗粒治疗小儿腹泻疗效及安全性的Meta分析[J].世界中医药,2017,12(8):1936-1940,5.基金项目
武汉大学“985工程”建设项目中央专项资金 （）
